Culture of primary DCs or DC and T cell co-cultures with PHCCC NPs reduced DC activation and secretion of pro-inflammatory cytokines, while shifting T cells away from TH17 and toward TREG phenotypes.
In contrast to this effect, the predominance of anti-inflammatory cytokines in healthy nonobese individuals shifts T cell and macrophage polarization toward Th2 and M2 phenotypes, respectively [ 100].
For behavioral measures, the subgroup comparisons showed relevant effect sizes only for attentional functions as indicated by TAP phasic alertness (T = 45.3 ± 12 and T = 48.1 ± 14; d = -0.32) and response shifting (T = 45.2 ± 15 and T = 50.7 ± 9; d = -0.40).
While GCs inhibit both Th1 and Th2 cytokines by activated human T cells, its effect on Th1 cytokines is more pronounced, shifting T cell response towards Th2 profiles [ 22].
In addition, macrophages play a vital role in regulating obese inflammation by the ability to shift T-helper (Th) cell differentiation toward the Th1 subtype, a pro-inflammatory condition [39].
In particular, IL-11 was shown to shift T-cell response towards a Th2 type [35], [36], modify hemopoiesis [35], [37], [38], and directly affect inflammation [35], [39] [41].
Furthermore, the prolonged 'absence' of B cells could also have important influences on the T cell repertoire either by decreasing T cell activation or by shifting T-helper cell polarization, presumably favoring a T-helper-1 profile [ 4, 5].
A more sensitive assay is to measure the ability of wild type protein synthesized during G2/M phase to suppress the loss of cohesion induced by shifting ts mutants to the restrictive temperature.
In summary, we demonstrate a failure of catecholamines to shift T-cell cytokine responses toward the expected Th2 profile in patients with RA; this failure thus generates a cytokine environment that perpetuates inflammation.
Alternatively, ipilimumab may amplify immune adaptation through shifting T-cell responses, a mechanism for overcoming immune tolerance that has been observed in a long-term survivor of metastatic melanoma in the absence of immunotherapy (Yamshchikov et al, 2005).
